Academic Journal
Προβολή σε EDS

HPV Prevalence Among Inuit Women in Northern Quebec, Canada: A Pre- and Post-Vaccination Analysis.

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τίτλος: HPV Prevalence Among Inuit Women in Northern Quebec, Canada: A Pre- and Post-Vaccination Analysis.
Συγγραφείς: Talib G; Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, QC, Canada.; Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, QC, Canada., Blais P; Family Planning Clinic, Ungava Tulattavik Health Center, Kuujjuaq, QC, Canada., Smith N; Planning and Programming Department, Nunavik Regional Board of Health and Social Services, Kuujjuaq, QC, Canada., Coutlée F; Department of Microbiology, Infectious Diseases and Immunology, Université de Montréal, Montreal, QC, Canada.; Departments of Clinical Laboratory Medicine and Medicine, Molecular Diagnostics and Medical Microbiology Services, Centre hospitalier de l'Université de Montréal, Montreal, QC, Canada., Franco EL; Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, QC, Canada.; Division of Cancer Epidemiology, McGill University, Montreal, QC, Canada., Brassard P; Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, QC, Canada.; Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, QC, Canada.; Department of Medicine, McGill University, Montreal, QC, Canada.
Πηγή: Journal of lower genital tract disease [J Low Genit Tract Dis] 2026 Jul 01; Vol. 30 (3), pp. 194-198. Date of Electronic Publication: 2026 Jul 01.
Τύπος έκδοσης: Journal Article
Γλώσσα: English
Στοιχεία περιοδικού: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 9704963 Publication Model: Electronic Cited Medium: Internet ISSN: 1526-0976 (Electronic) Linking ISSN: 10892591 NLM ISO Abbreviation: J Low Genit Tract Dis Subsets: MEDLINE
Imprint Name(s): Publication: 2002- : Hagerstown, MD : Lippincott Williams & Wilkins
Original Publication: Malden, MA : Blackwell Science Inc., c1997-
Ιατρικοί όροι (MeSH): Papillomavirus Infections*/epidemiology , Papillomavirus Infections*/prevention & control , Inuit*/statistics & numerical data , Papillomavirus Vaccines*/administration & dosage , Papillomaviridae*/isolation & purification , Papillomaviridae*/genetics , Papillomaviridae*/classification, Quebec/epidemiology ; Vaccination/statistics & numerical data ; Humans ; Female ; Prevalence ; Middle Aged ; Adult ; Aged ; DNA, Viral
Περίληψη: Objective: To assess changes in high-risk HPV prevalence among Inuit women in Nunavik following the introduction in 2008 among 12-year-old girls of the quadrivalent HPV vaccine program in Quebec.
Methods: A total of 169 Inuit women aged 25-65 were recruited in Kuujjuaq, Nunavik, between July 2022 and December 2024. Participants self-collected cervico-vaginal samples under nurse supervision. HPV DNA testing was performed using real-time PCR (Cobas 4800), detecting HPV 16, 18, and 12 other high-risk types. Results were compared with historical data from 473 Inuit women (2002-2007), using the same genotypic categories. Age-stratified prevalence ratios (PR) were calculated to assess differences over time and odds ratios (OR) for HPV 16/18 detection by vaccination status.
Results: Among 148 participants with results, overall high-risk HPV prevalence increased from 15.9% pre-vaccination to 22.3% post-vaccination, driven by a significant rise in other high-risk types among women aged 40+ (from 5.8% to 16.4%; PR=2.80, 95% CI: 1.16-6.75). HPV 16/18 prevalence showed a non-statistically significant decline among the 25-29 age group (6.8%-3.3%). Only one vaccinated participant tested positive for HPV 16/18 (OR=0.29, 95% CI: 0.0062-2.54).
Conclusions: The quadrivalent HPV vaccine has reduced HPV 16/18 prevalence in the targeted younger population. Continued surveillance is warranted, particularly for nonvaccine high-risk types.
(Copyright © 2026 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the ASCCP.)
Competing Interests: The authors have declared they have no conflicts of interest.
References: Burd EM. Human papillomavirus and cervical cancer. Clin Microbiol Rev 2003;16:1–17.
de Martel C, Georges D, Bray F, et al. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health 2020;8:e180–e190.
Louchini R, Beaupré M. Cancer incidence and mortality among Aboriginal people living on reserves and northern villages in Quebec, 1988–2004. Int J Circumpolar Health 2008;67:445–451.
Ahmed S, Shahid RK, Episkenew JA. Disparity in cancer prevention and screening in aboriginal populations: recommendations for action. Curr Oncol 2015;22:417.
Young TK, Kelly JJ, Friborg J, et al. Cancer among circumpolar populations: an emerging public health concern. Int J Circumpolar Health 2016;75:29787.
Gamelin R, Hébert M, Tratt E, et al. Ethnographic study of the barriers and facilitators to implementing HPV self-sampling as a primary screening strategy for cervical cancer among Inuit women of Nunavik, Northern Quebec. Int J Circumpolar Health 2022;81:2032930.
Institut national de santé publique du Québec. HPV Vaccination in Québec: Knowledge Update and Expert Panel Proposals. Published 2012. Accessed July 9, 2025. https://www.inspq.qc.ca/pdf/publications/1473_HPV_Vaccination_Qc_ExpertPanel_Proposals.pdf.
Basu P, Malvi SG, Joshi S, et al. Vaccine efficacy against persistent HPV 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study. Lancet Oncol 2021;22:1518–1529.
Drolet M, Bénard É, Pérez N, et al; HPV Vaccination Impact Study Group. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet 2019;394:497–509.
Checchi M, Mesher D, Panwar K, et al. The impact of over ten years of HPV vaccination in England: surveillance of type-specific HPV in young sexually active females. Vaccine 2023;41:6734–6744.
Seyoum A, Seyoum B, Gure T, et al. High rate of non-vaccine targeted high-risk HPV genotypes circulate among women in Eastern Ethiopia. Sci Rep 2024;14:958.
Gray P, Wang J, Nordqvist Kleppe S, et al. Population-based age-period-cohort analysis of declining human papillomavirus prevalence. J Infect Dis 2025;231:e638–e649.
Gosselin G, Blais P, Smith N, et al. Cervical cancer screening preference among Inuit women in Nunavik, Quebec. Int J Circumpolar Health 2024;83:2429860.
Cerigo H, Coutlée F, Franco EL, et al. Factors associated with cervical cancer screening uptake among Inuit women in Nunavik, Quebec, Canada. BMC Public Health 2013;13:1–8.
Statistics Canada. Profile table, Census Profile, 2021 Census of Population, Kuujjuaq, Village nordique (VN) [Census subdivision], Quebec. Ottawa, ON: Statistics Canada. Accessed November 15, 2023. https://www12.statcan.gc.ca/census-recensement/2021/dp-pd/prof/index.cfm?Lang=E.
Grandjean Lapierre S, Sauthier P, Mayrand MH, et al. Human papillomavirus (HPV) DNA triage of women with atypical squamous cells of undetermined significance (ASC-US) with Cobas 4800 HPV and Hybrid Capture 2 tests for detection of high-grade lesions of the uterine cervix. J Clin Microbiol 2012;50:1240–1244.
Hamlin-Douglas LK, Coutlée F, Roger M, et al. Prevalence and age distribution of human papillomavirus infection in a population of Inuit women in Nunavik, Quebec. Cancer Epidemiol Biomarkers Prev 2008;17:3141–3149.
Coutlée F, Rouleau D, Petignat P, et al; The Canadian women HIV Study Group, Franco E. Enhanced detection and typing of human papillomavirus DNA in anogenital samples with PGMY primers and the LINEAR ARRAY HPV genotyping test. J Clin Microbiol 2006;44:1998–2006.
R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing; 2024. https://www.R-project.org/.
Muhr LSA, Gini A, Yilmaz E, et al. Concomitant human papillomavirus (HPV) vaccination and screening for elimination of HPV and cervical cancer. Nat Commun 2024;15:3679.
Sauvageau C, Mayrand MH, Ouakki M, et al. Protection against persistent HPV-16/18 infection after different number of doses of quadrivalent vaccine in girls and young women: a randomized clinical trial. JAMA Netw Open 2025;8:e2519095.
Harper DM, Navarro-Alonso JA, Bosch FX, et al. Impact of human papillomavirus vaccines in the reduction of infection, precursor lesions, and cervical cancer: a systematic literature review. Hum Vaccin Immunother 2025;21:2497608.
Osmani V, Rossiter M, Hörner L, et al. Worldwide burden of cervical human papillomavirus (HPV) in women over 50 years with abnormal cytology: a systematic review and meta-analysis. BMJ Glob Health 2025;10:e017309.
Syrjänen K, Kulmala SM, Shabalova I, et al. Epidemiological, clinical and viral determinants of the increased prevalence of high-risk human papillomavirus (HPV) infections in elderly women. Eur J Gynaecol Oncol 2008;29:114–123.
Korostil IA, Regan DG. The potential impact of HPV-16 reactivation on prevalence in older Australians. BMC Infect Dis 2014;14:312.
Tesfaye E, Kumbi B, Mandefro B, et al. Prevalence of human papillomavirus infection and associated factors among women attending cervical cancer screening in setting of Addis Ababa, Ethiopia. Sci Rep 2024;14:4053.
Gouvernement du Québec. Cervical cancer screening: primary HPV test. 2023. Accessed July 9, 2025. https://www.quebec.ca/en/health/advice-and-prevention/screening-and-carrier-testing-offer/cervical-cancer-screening.
World Health Organization. Global Strategy to Accelerate the Elimination of Cervical Cancer as a Public Health Problem. 2020. Accessed July 9, 2025. https://www.who.int/publications/i/item/9789240014107.
Comité sur l’immunisation du Québec. Avis du Comité sur l’immunisation du Québec sur la vaccination contre les virus du papillome humain (VPH) avec le vaccin nonavalent Gardasil 9. Institut national de santé publique du Québec; 2018. Accessed July 9, 2025. https://www.inspq.qc.ca/publications/2342.
Laprise JF, Chesson HW, Markowitz LE, et al. Cost-effectiveness of extending human papillomavirus vaccination to population subgroups older than 26 years who are at higher risk for human papillomavirus infection in the United States. Ann Intern Med 2025;178:50–58.
Contributed Indexing: Keywords: HPV vaccines; Quebec; cervical cancer prevention; high-risk HPV; human papillomavirus infections; indigenous health services; inuit; prevalence; self-sampling; vaccination programs
Substance Nomenclature: 0 (Papillomavirus Vaccines)
0 (DNA, Viral)
Entry Date(s): Date Created: 20260415 Date Completed: 20260623 Latest Revision: 20260707
Update Code: 20260708
DOI: 10.1097/LGT.0000000000000953
PMID: 41985196
Βάση Δεδομένων: MEDLINE
Περιγραφή
ISSN:1526-0976
DOI:10.1097/LGT.0000000000000953